Global Mebendazole Market

Mebendazole Comprehensive Study by Type (≥98%, ≥99%), End users (Below 2 Years Old, Above 2 Years 5Old), Form (Feed Additives, Tablet, Oral Suspension) Players and Region - Global Market Outlook to 2026

Mebendazole Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Mebendazole is a type of medication which is used for the treatment of parasitic worm infections. The infections include ascariasis, pinworm disease, hookworm infections, guinea worm infections, hydatid disease, and giardia. It prevents newly hatched insect larvae (worms) from growing or multiplying in the body. Moreover, Mebendazole is a white to slightly yellow powder with molecular weight of 295.29. It is less than 0.05% soluble in water, dilute mineral acid solutions, alcohol, but soluble in formic acid. However, it has side effects such as headache, vomiting, and ringing in the ears.This growth is primarily driven by Prevalence of Intestinal Infections is Fuelling the Market and Increasing Usage of Mebendazole is Fuelling the Market.

Major Players, such as Johnson & Johnson (United States), Amneal Pharmaceuticals (United States), Cadila Pharmaceuticals (India), Eipico (Egypt), Esteve Pharmaceuticals (Spain), K A malle (India), Surya (India), GNH India (India), Changzhou Yabang-QH Pharmachem (China) and Aarambh Life Science (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Prevalence of Intestinal Infections is Fuelling the Market
  • Increasing Usage of Mebendazole is Fuelling the Market

Market Trend

Restraints
  • Availability Alternative Options May Hamper the Market
  • Stringent Government Regulations

Opportunities
Rising Research and Developments is Boosting the Market
Challenges
Side Effects of a Mebendazole

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Mebendazole Study Sheds Light on
— The Mebendazole Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Mebendazole industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Mebendazole industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • ≥98%
  • ≥99%
By End users
  • Below 2 Years Old
  • Above 2 Years 5Old

By Form
  • Feed Additives
  • Tablet
  • Oral Suspension

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Intestinal Infections is Fuelling the Market
      • 3.2.2. Increasing Usage of Mebendazole is Fuelling the Market
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of a Mebendazole
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mebendazole, by Type, End users, Form and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Mebendazole (Value)
      • 5.2.1. Global Mebendazole by: Type (Value)
        • 5.2.1.1. ≥98%
        • 5.2.1.2. ≥99%
      • 5.2.2. Global Mebendazole by: End users (Value)
        • 5.2.2.1. Below 2 Years Old
        • 5.2.2.2. Above 2 Years 5Old
      • 5.2.3. Global Mebendazole by: Form (Value)
        • 5.2.3.1. Feed Additives
        • 5.2.3.2. Tablet
        • 5.2.3.3. Oral Suspension
      • 5.2.4. Global Mebendazole Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Mebendazole (Price)
      • 5.3.1. Global Mebendazole by: Type (Price)
  • 6. Mebendazole: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amneal Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cadila Pharmaceuticals (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eipico (Egypt)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Esteve Pharmaceuticals (Spain)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. K A malle (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Surya (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GNH India (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Changzhou Yabang-QH Pharmachem (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aarambh Life Science (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mebendazole Sale, by Type, End users, Form and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Mebendazole (Value)
      • 7.2.1. Global Mebendazole by: Type (Value)
        • 7.2.1.1. ≥98%
        • 7.2.1.2. ≥99%
      • 7.2.2. Global Mebendazole by: End users (Value)
        • 7.2.2.1. Below 2 Years Old
        • 7.2.2.2. Above 2 Years 5Old
      • 7.2.3. Global Mebendazole by: Form (Value)
        • 7.2.3.1. Feed Additives
        • 7.2.3.2. Tablet
        • 7.2.3.3. Oral Suspension
      • 7.2.4. Global Mebendazole Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Mebendazole (Price)
      • 7.3.1. Global Mebendazole by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mebendazole: by Type(USD Million)
  • Table 2. Mebendazole ≥98% , by Region USD Million (2015-2020)
  • Table 3. Mebendazole ≥99% , by Region USD Million (2015-2020)
  • Table 4. Mebendazole: by End users(USD Million)
  • Table 5. Mebendazole Below 2 Years Old , by Region USD Million (2015-2020)
  • Table 6. Mebendazole Above 2 Years 5Old , by Region USD Million (2015-2020)
  • Table 7. Mebendazole: by Form(USD Million)
  • Table 8. Mebendazole Feed Additives , by Region USD Million (2015-2020)
  • Table 9. Mebendazole Tablet , by Region USD Million (2015-2020)
  • Table 10. Mebendazole Oral Suspension , by Region USD Million (2015-2020)
  • Table 11. South America Mebendazole, by Country USD Million (2015-2020)
  • Table 12. South America Mebendazole, by Type USD Million (2015-2020)
  • Table 13. South America Mebendazole, by End users USD Million (2015-2020)
  • Table 14. South America Mebendazole, by Form USD Million (2015-2020)
  • Table 15. Brazil Mebendazole, by Type USD Million (2015-2020)
  • Table 16. Brazil Mebendazole, by End users USD Million (2015-2020)
  • Table 17. Brazil Mebendazole, by Form USD Million (2015-2020)
  • Table 18. Argentina Mebendazole, by Type USD Million (2015-2020)
  • Table 19. Argentina Mebendazole, by End users USD Million (2015-2020)
  • Table 20. Argentina Mebendazole, by Form USD Million (2015-2020)
  • Table 21. Rest of South America Mebendazole, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Mebendazole, by End users USD Million (2015-2020)
  • Table 23. Rest of South America Mebendazole, by Form USD Million (2015-2020)
  • Table 24. Asia Pacific Mebendazole, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Mebendazole, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Mebendazole, by End users USD Million (2015-2020)
  • Table 27. Asia Pacific Mebendazole, by Form USD Million (2015-2020)
  • Table 28. China Mebendazole, by Type USD Million (2015-2020)
  • Table 29. China Mebendazole, by End users USD Million (2015-2020)
  • Table 30. China Mebendazole, by Form USD Million (2015-2020)
  • Table 31. Japan Mebendazole, by Type USD Million (2015-2020)
  • Table 32. Japan Mebendazole, by End users USD Million (2015-2020)
  • Table 33. Japan Mebendazole, by Form USD Million (2015-2020)
  • Table 34. India Mebendazole, by Type USD Million (2015-2020)
  • Table 35. India Mebendazole, by End users USD Million (2015-2020)
  • Table 36. India Mebendazole, by Form USD Million (2015-2020)
  • Table 37. South Korea Mebendazole, by Type USD Million (2015-2020)
  • Table 38. South Korea Mebendazole, by End users USD Million (2015-2020)
  • Table 39. South Korea Mebendazole, by Form USD Million (2015-2020)
  • Table 40. Taiwan Mebendazole, by Type USD Million (2015-2020)
  • Table 41. Taiwan Mebendazole, by End users USD Million (2015-2020)
  • Table 42. Taiwan Mebendazole, by Form USD Million (2015-2020)
  • Table 43. Australia Mebendazole, by Type USD Million (2015-2020)
  • Table 44. Australia Mebendazole, by End users USD Million (2015-2020)
  • Table 45. Australia Mebendazole, by Form USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Mebendazole, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Mebendazole, by End users USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Mebendazole, by Form USD Million (2015-2020)
  • Table 49. Europe Mebendazole, by Country USD Million (2015-2020)
  • Table 50. Europe Mebendazole, by Type USD Million (2015-2020)
  • Table 51. Europe Mebendazole, by End users USD Million (2015-2020)
  • Table 52. Europe Mebendazole, by Form USD Million (2015-2020)
  • Table 53. Germany Mebendazole, by Type USD Million (2015-2020)
  • Table 54. Germany Mebendazole, by End users USD Million (2015-2020)
  • Table 55. Germany Mebendazole, by Form USD Million (2015-2020)
  • Table 56. France Mebendazole, by Type USD Million (2015-2020)
  • Table 57. France Mebendazole, by End users USD Million (2015-2020)
  • Table 58. France Mebendazole, by Form USD Million (2015-2020)
  • Table 59. Italy Mebendazole, by Type USD Million (2015-2020)
  • Table 60. Italy Mebendazole, by End users USD Million (2015-2020)
  • Table 61. Italy Mebendazole, by Form USD Million (2015-2020)
  • Table 62. United Kingdom Mebendazole, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Mebendazole, by End users USD Million (2015-2020)
  • Table 64. United Kingdom Mebendazole, by Form USD Million (2015-2020)
  • Table 65. Netherlands Mebendazole, by Type USD Million (2015-2020)
  • Table 66. Netherlands Mebendazole, by End users USD Million (2015-2020)
  • Table 67. Netherlands Mebendazole, by Form USD Million (2015-2020)
  • Table 68. Rest of Europe Mebendazole, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Mebendazole, by End users USD Million (2015-2020)
  • Table 70. Rest of Europe Mebendazole, by Form USD Million (2015-2020)
  • Table 71. MEA Mebendazole, by Country USD Million (2015-2020)
  • Table 72. MEA Mebendazole, by Type USD Million (2015-2020)
  • Table 73. MEA Mebendazole, by End users USD Million (2015-2020)
  • Table 74. MEA Mebendazole, by Form USD Million (2015-2020)
  • Table 75. Middle East Mebendazole, by Type USD Million (2015-2020)
  • Table 76. Middle East Mebendazole, by End users USD Million (2015-2020)
  • Table 77. Middle East Mebendazole, by Form USD Million (2015-2020)
  • Table 78. Africa Mebendazole, by Type USD Million (2015-2020)
  • Table 79. Africa Mebendazole, by End users USD Million (2015-2020)
  • Table 80. Africa Mebendazole, by Form USD Million (2015-2020)
  • Table 81. North America Mebendazole, by Country USD Million (2015-2020)
  • Table 82. North America Mebendazole, by Type USD Million (2015-2020)
  • Table 83. North America Mebendazole, by End users USD Million (2015-2020)
  • Table 84. North America Mebendazole, by Form USD Million (2015-2020)
  • Table 85. United States Mebendazole, by Type USD Million (2015-2020)
  • Table 86. United States Mebendazole, by End users USD Million (2015-2020)
  • Table 87. United States Mebendazole, by Form USD Million (2015-2020)
  • Table 88. Canada Mebendazole, by Type USD Million (2015-2020)
  • Table 89. Canada Mebendazole, by End users USD Million (2015-2020)
  • Table 90. Canada Mebendazole, by Form USD Million (2015-2020)
  • Table 91. Mexico Mebendazole, by Type USD Million (2015-2020)
  • Table 92. Mexico Mebendazole, by End users USD Million (2015-2020)
  • Table 93. Mexico Mebendazole, by Form USD Million (2015-2020)
  • Table 94. Mebendazole: by Type(USD/Units)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Mebendazole: by Type(USD Million)
  • Table 106. Mebendazole ≥98% , by Region USD Million (2021-2026)
  • Table 107. Mebendazole ≥99% , by Region USD Million (2021-2026)
  • Table 108. Mebendazole: by End users(USD Million)
  • Table 109. Mebendazole Below 2 Years Old , by Region USD Million (2021-2026)
  • Table 110. Mebendazole Above 2 Years 5Old , by Region USD Million (2021-2026)
  • Table 111. Mebendazole: by Form(USD Million)
  • Table 112. Mebendazole Feed Additives , by Region USD Million (2021-2026)
  • Table 113. Mebendazole Tablet , by Region USD Million (2021-2026)
  • Table 114. Mebendazole Oral Suspension , by Region USD Million (2021-2026)
  • Table 115. South America Mebendazole, by Country USD Million (2021-2026)
  • Table 116. South America Mebendazole, by Type USD Million (2021-2026)
  • Table 117. South America Mebendazole, by End users USD Million (2021-2026)
  • Table 118. South America Mebendazole, by Form USD Million (2021-2026)
  • Table 119. Brazil Mebendazole, by Type USD Million (2021-2026)
  • Table 120. Brazil Mebendazole, by End users USD Million (2021-2026)
  • Table 121. Brazil Mebendazole, by Form USD Million (2021-2026)
  • Table 122. Argentina Mebendazole, by Type USD Million (2021-2026)
  • Table 123. Argentina Mebendazole, by End users USD Million (2021-2026)
  • Table 124. Argentina Mebendazole, by Form USD Million (2021-2026)
  • Table 125. Rest of South America Mebendazole, by Type USD Million (2021-2026)
  • Table 126. Rest of South America Mebendazole, by End users USD Million (2021-2026)
  • Table 127. Rest of South America Mebendazole, by Form USD Million (2021-2026)
  • Table 128. Asia Pacific Mebendazole, by Country USD Million (2021-2026)
  • Table 129. Asia Pacific Mebendazole, by Type USD Million (2021-2026)
  • Table 130. Asia Pacific Mebendazole, by End users USD Million (2021-2026)
  • Table 131. Asia Pacific Mebendazole, by Form USD Million (2021-2026)
  • Table 132. China Mebendazole, by Type USD Million (2021-2026)
  • Table 133. China Mebendazole, by End users USD Million (2021-2026)
  • Table 134. China Mebendazole, by Form USD Million (2021-2026)
  • Table 135. Japan Mebendazole, by Type USD Million (2021-2026)
  • Table 136. Japan Mebendazole, by End users USD Million (2021-2026)
  • Table 137. Japan Mebendazole, by Form USD Million (2021-2026)
  • Table 138. India Mebendazole, by Type USD Million (2021-2026)
  • Table 139. India Mebendazole, by End users USD Million (2021-2026)
  • Table 140. India Mebendazole, by Form USD Million (2021-2026)
  • Table 141. South Korea Mebendazole, by Type USD Million (2021-2026)
  • Table 142. South Korea Mebendazole, by End users USD Million (2021-2026)
  • Table 143. South Korea Mebendazole, by Form USD Million (2021-2026)
  • Table 144. Taiwan Mebendazole, by Type USD Million (2021-2026)
  • Table 145. Taiwan Mebendazole, by End users USD Million (2021-2026)
  • Table 146. Taiwan Mebendazole, by Form USD Million (2021-2026)
  • Table 147. Australia Mebendazole, by Type USD Million (2021-2026)
  • Table 148. Australia Mebendazole, by End users USD Million (2021-2026)
  • Table 149. Australia Mebendazole, by Form USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Mebendazole, by Type USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Mebendazole, by End users USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Mebendazole, by Form USD Million (2021-2026)
  • Table 153. Europe Mebendazole, by Country USD Million (2021-2026)
  • Table 154. Europe Mebendazole, by Type USD Million (2021-2026)
  • Table 155. Europe Mebendazole, by End users USD Million (2021-2026)
  • Table 156. Europe Mebendazole, by Form USD Million (2021-2026)
  • Table 157. Germany Mebendazole, by Type USD Million (2021-2026)
  • Table 158. Germany Mebendazole, by End users USD Million (2021-2026)
  • Table 159. Germany Mebendazole, by Form USD Million (2021-2026)
  • Table 160. France Mebendazole, by Type USD Million (2021-2026)
  • Table 161. France Mebendazole, by End users USD Million (2021-2026)
  • Table 162. France Mebendazole, by Form USD Million (2021-2026)
  • Table 163. Italy Mebendazole, by Type USD Million (2021-2026)
  • Table 164. Italy Mebendazole, by End users USD Million (2021-2026)
  • Table 165. Italy Mebendazole, by Form USD Million (2021-2026)
  • Table 166. United Kingdom Mebendazole, by Type USD Million (2021-2026)
  • Table 167. United Kingdom Mebendazole, by End users USD Million (2021-2026)
  • Table 168. United Kingdom Mebendazole, by Form USD Million (2021-2026)
  • Table 169. Netherlands Mebendazole, by Type USD Million (2021-2026)
  • Table 170. Netherlands Mebendazole, by End users USD Million (2021-2026)
  • Table 171. Netherlands Mebendazole, by Form USD Million (2021-2026)
  • Table 172. Rest of Europe Mebendazole, by Type USD Million (2021-2026)
  • Table 173. Rest of Europe Mebendazole, by End users USD Million (2021-2026)
  • Table 174. Rest of Europe Mebendazole, by Form USD Million (2021-2026)
  • Table 175. MEA Mebendazole, by Country USD Million (2021-2026)
  • Table 176. MEA Mebendazole, by Type USD Million (2021-2026)
  • Table 177. MEA Mebendazole, by End users USD Million (2021-2026)
  • Table 178. MEA Mebendazole, by Form USD Million (2021-2026)
  • Table 179. Middle East Mebendazole, by Type USD Million (2021-2026)
  • Table 180. Middle East Mebendazole, by End users USD Million (2021-2026)
  • Table 181. Middle East Mebendazole, by Form USD Million (2021-2026)
  • Table 182. Africa Mebendazole, by Type USD Million (2021-2026)
  • Table 183. Africa Mebendazole, by End users USD Million (2021-2026)
  • Table 184. Africa Mebendazole, by Form USD Million (2021-2026)
  • Table 185. North America Mebendazole, by Country USD Million (2021-2026)
  • Table 186. North America Mebendazole, by Type USD Million (2021-2026)
  • Table 187. North America Mebendazole, by End users USD Million (2021-2026)
  • Table 188. North America Mebendazole, by Form USD Million (2021-2026)
  • Table 189. United States Mebendazole, by Type USD Million (2021-2026)
  • Table 190. United States Mebendazole, by End users USD Million (2021-2026)
  • Table 191. United States Mebendazole, by Form USD Million (2021-2026)
  • Table 192. Canada Mebendazole, by Type USD Million (2021-2026)
  • Table 193. Canada Mebendazole, by End users USD Million (2021-2026)
  • Table 194. Canada Mebendazole, by Form USD Million (2021-2026)
  • Table 195. Mexico Mebendazole, by Type USD Million (2021-2026)
  • Table 196. Mexico Mebendazole, by End users USD Million (2021-2026)
  • Table 197. Mexico Mebendazole, by Form USD Million (2021-2026)
  • Table 198. Mebendazole: by Type(USD/Units)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mebendazole: by Type USD Million (2015-2020)
  • Figure 5. Global Mebendazole: by End users USD Million (2015-2020)
  • Figure 6. Global Mebendazole: by Form USD Million (2015-2020)
  • Figure 7. South America Mebendazole Share (%), by Country
  • Figure 8. Asia Pacific Mebendazole Share (%), by Country
  • Figure 9. Europe Mebendazole Share (%), by Country
  • Figure 10. MEA Mebendazole Share (%), by Country
  • Figure 11. North America Mebendazole Share (%), by Country
  • Figure 12. Global Mebendazole: by Type USD/Units (2015-2020)
  • Figure 13. Global Mebendazole share by Players 2020 (%)
  • Figure 14. Global Mebendazole share by Players (Top 3) 2020(%)
  • Figure 15. Global Mebendazole share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 18. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 19. Amneal Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 20. Amneal Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 21. Cadila Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 22. Cadila Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 23. Eipico (Egypt) Revenue, Net Income and Gross profit
  • Figure 24. Eipico (Egypt) Revenue: by Geography 2020
  • Figure 25. Esteve Pharmaceuticals (Spain) Revenue, Net Income and Gross profit
  • Figure 26. Esteve Pharmaceuticals (Spain) Revenue: by Geography 2020
  • Figure 27. K A malle (India) Revenue, Net Income and Gross profit
  • Figure 28. K A malle (India) Revenue: by Geography 2020
  • Figure 29. Surya (India) Revenue, Net Income and Gross profit
  • Figure 30. Surya (India) Revenue: by Geography 2020
  • Figure 31. GNH India (India) Revenue, Net Income and Gross profit
  • Figure 32. GNH India (India) Revenue: by Geography 2020
  • Figure 33. Changzhou Yabang-QH Pharmachem (China) Revenue, Net Income and Gross profit
  • Figure 34. Changzhou Yabang-QH Pharmachem (China) Revenue: by Geography 2020
  • Figure 35. Aarambh Life Science (India) Revenue, Net Income and Gross profit
  • Figure 36. Aarambh Life Science (India) Revenue: by Geography 2020
  • Figure 37. Global Mebendazole: by Type USD Million (2021-2026)
  • Figure 38. Global Mebendazole: by End users USD Million (2021-2026)
  • Figure 39. Global Mebendazole: by Form USD Million (2021-2026)
  • Figure 40. South America Mebendazole Share (%), by Country
  • Figure 41. Asia Pacific Mebendazole Share (%), by Country
  • Figure 42. Europe Mebendazole Share (%), by Country
  • Figure 43. MEA Mebendazole Share (%), by Country
  • Figure 44. North America Mebendazole Share (%), by Country
  • Figure 45. Global Mebendazole: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson (United States)
  • Amneal Pharmaceuticals (United States)
  • Cadila Pharmaceuticals (India)
  • Eipico (Egypt)
  • Esteve Pharmaceuticals (Spain)
  • K A malle (India)
  • Surya (India)
  • GNH India (India)
  • Changzhou Yabang-QH Pharmachem (China)
  • Aarambh Life Science (India)
Additional players considered in the study are as follows:
Neha Pharma Private Limited (India) , Adani Pharmachem Private Limited (India) , Shanghai Ziqi Biotechnology (China)
Select User Access Type

Key Highlights of Report


Oct 2021 141 Pages 91 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Mebendazole Market Quantitative research analysis
Global Mebendazole Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Mebendazole Market are Johnson & Johnson (United States), Amneal Pharmaceuticals (United States), Cadila Pharmaceuticals (India), Eipico (Egypt), Esteve Pharmaceuticals (Spain), K A malle (India), Surya (India), GNH India (India), Changzhou Yabang-QH Pharmachem (China) and Aarambh Life Science (India) etc.
Mebendazole is a type of medication which is used for the treatment of parasitic worm infections. The infections include ascariasis, pinworm disease, hookworm infections, guinea worm infections, hydatid disease, and giardia. It prevents newly hatched insect larvae (worms) from growing or multiplying in the body. Moreover, Mebendazole is a white to slightly yellow powder with molecular weight of 295.29. It is less than 0.05% soluble in water, dilute mineral acid solutions, alcohol, but soluble in formic acid. However, it has side effects such as headache, vomiting, and ringing in the ears.

Know More About Global Mebendazole Market Report?

Have a Query? Click Here

Other Related Reports

Pharmacy Benefit Management Services Comprehensive Study by Type (Commercial Health Plans, Self-Insured Employer Plans, Medicare Part D Plans, Federal Employees Health Benefits Program, State Governm...
$ 3750
Levonorgestrel API Comprehensive Study by Type (Innovative API, Generic API), Application (Birth Control, Hormone Therapy), Drugs Type (Prescription Drugs, Over-the-counter Drugs), Grade (BP (British...
$ 3650
Blockchain in Pharmaceutical Comprehensive Study by Type (Public, Private, Consortium), Application (Supply Chain Management, Clinical Data Exchange and Interoperability, Drug Development, Clinical T...
$ 3450
Triptorelin Comprehensive Study by Type (Triptorelin Pamoate, Triptorelin Acetate, Triptorelin Embonate), Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer, Ce...
$ 3450
Fingolimod Comprehensive Study by Application (Medical Field, Science Research Field, Other Field), Administration (Oral, Injection), Distribution Channel (Healthcare Providers, Online Pharmacies, Me...
$ 3350
Cannabinoid Drugs Comprehensive Study by Type (Phytocannabinoids, Endocannabinoids, Synthetics), Application (Chronic Diseases, Anxiety, Nausea, Others), End-users (Hospitals, Clinics, Ambulatory Sur...
$ 3650